Zoetis acquires pet care genetics company
LA-based Basepaws will be able to enhance its R&D capabilities and future innovations thanks to its database of feline genomics.
The acquisition is set to upgrade the Zoetis portfolio in the precision animal health space across genetics and diagnostics data analytics for pets.
“We are excited by how Basepaws’ feline genomic and microbiome database will help enhance our R&D capabilities and inform the future of our petcare pipeline,” stated Abhay Nayak, Executive Vice President of Strategy, Accelerated Growth Businesses and Commercial Development.
The pet care genetics firm claims to have one of the world’s largest feline genomic and oral microbiome databases, useful for verifying traits and health conditions for today’s cats.
“We look forward to expanding our business and the impact of our genetic products with the global scale and R&D experience of Zoetis,” declared Basepaws CEO Anna Skaya.
Founded in 2017, Basepaws provides pet owners with genetic tests, analytics and early health risk assessments that can help manage the health, wellbeing and quality of care for their pets.
Zoetis posted $7.8 billion (€7.4B) in revenue in 2021, 16% more than in 2020. Net income for the full year 2021 was $2.0 billion (€1.9B), an increase of 24%.